Cargando…

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation

Genotype-guided warfarin dosing have been proposed to improve patient’s management. This study is aimed to determine whether a CYP2C9- VKORC1- CYP4F2-based pharmacogenetic algorithm is superior to a standard, clinically adopted, pharmacodynamic method. Two-hundred naïve patients with non-valvular at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pengo, Vittorio, Zambon, Carlo-Federico, Fogar, Paola, Padoan, Andrea, Nante, Giovanni, Pelloso, Michela, Moz, Stefania, Frigo, Anna Chiara, Groppa, Francesca, Bozzato, Dania, Tiso, Enrico, Gnatta, Elisa, Denas, Gentian, Padayattil Jose, Seena, Padrini, Roberto, Basso, Daniela, Plebani, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692529/ https://www.ncbi.nlm.nih.gov/pubmed/26710337 http://dx.doi.org/10.1371/journal.pone.0145318

Ejemplares similares

Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1
por: Basso, Daniela, et al.
Publicado: (2014)

PDAC-derived exosomes enrich the microenvironment in MDSCs in a SMAD4-dependent manner through a new calcium related axis
por: Basso, Daniela, et al.
Publicado: (2017)

Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study
por: Basso, Daniela, et al.
Publicado: (2013)

TNFA Haplotype Genetic Testing Improves HLA in Estimating the Risk of Celiac Disease in Children
por: Rossi, Elisa, et al.
Publicado: (2015)

MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers
por: Padoan, Andrea, et al.
Publicado: (2018)

SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells
por: Moz, Stefania, et al.
Publicado: (2016)

Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile
por: Di Maso, Vittorio, et al.
Publicado: (2014)

Systematic Review of Pharmacogenetic Warfarin Dosing
por: van Schie, Rianne M. F., et al.
Publicado: (2009)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012)

Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy
por: Aita, Ada, et al.
Publicado: (2018)

Warfarin pharmacogenetics: How close are we to clinical practice?
por: Gaikwad, Tejasvita, et al.
Publicado: (2013)

Warfarin Dosage Response Related Pharmacogenetics in Chinese Population
por: Li, Siyue, et al.
Publicado: (2015)

Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database
por: Liu, Rong, et al.
Publicado: (2015)

Salivary SARS-CoV-2 antigen rapid detection: A prospective cohort study
por: Basso, Daniela, et al.
Publicado: (2021)

Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
por: Padoan, Andrea, et al.
Publicado: (2020)

The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort
por: Al Ammari, Maha, et al.
Publicado: (2020)

Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study
por: Denas, Gentian, et al.
Publicado: (2021)

Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome
por: Pengo, Vittorio, et al.
Publicado: (2020)

Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients
por: Galvez, Jubby Marcela, et al.
Publicado: (2018)

The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression
por: Basso, Daniela, et al.
Publicado: (2013)

Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin
por: Kangelaris, Kirsten Neudoerffer, et al.
Publicado: (2009)

Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model
por: Mazzaccara, Cristina, et al.
Publicado: (2013)

Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm
por: Pei, Lin, et al.
Publicado: (2018)

Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina
por: Ašić, Adna, et al.
Publicado: (2019)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

A Pharmacogenetics-Based Warfarin Maintenance Dosing Algorithm from Northern Chinese Patients
por: Chen, Jinxing, et al.
Publicado: (2014)

A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics
por: Duconge, Jorge, et al.
Publicado: (2016)

Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds
por: Chang, Grace Shu-wen, et al.
Publicado: (2020)

Pharmacogenetic-Guided Algorithm to Improve Daily Dose of Warfarin in Elder Han-Chinese Population
por: Ren, Yirong, et al.
Publicado: (2020)

Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data
por: Roche-Lima, Abiel, et al.
Publicado: (2020)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores)
por: Branco, Claudia C, et al.
Publicado: (2009)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
por: Hamberg, Anna-Karin, et al.
Publicado: (2013)

Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials
por: Shi, Changcheng, et al.
Publicado: (2015)

An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions
por: Emmi, Giacomo, et al.
Publicado: (2014)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l8ak9ncboknfmmutltbgo4s866